Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1652W HIGH $5.24
Volume
4.40 K
Value Traded
14.97 K
Short % Float
1.52%
-1.35%Week
+3.55%1 Month
-12.57%3 Month
+20.66%6 Month
-92.72%5 Year
-99.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.33 M
EPS (TTM)
-1.10
P/E Ratio
-
Ent. Value
3.16 M
Total Shares
3.65 M
Float Shares
3.65 M
Insiders
0.00%
Institutions
9.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PULM Catalyst Timeline
Dated clinical, regulatory and corporate events for Pulmatrix, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pulmatrix, Inc.
324Total events
7Upcoming
100Tier-1 (high impact)
2014 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Runway Guidance UpdateCorporate
Cash sufficient to fund operations through anticipated merger close
▼Equity OfferingCorporate
Closing of Series B Preferred Stock private placement with Eos affiliate
▼Equity OfferingCorporate
Private placement of Series B Convertible Preferred Stock raising $1.0 million
▲Enrollment CompleteTrial
Cullgen's pain degrader program completed enrollment
acute and chronic painsource ↗
▲FDA Filing AcceptedRegulatory Filing
SEC declared registration statement effective for merger
◆Pipeline PrioritizationCorporate
Divestment process for iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900)
◆First Patient DosedTrial
CG001419 pain trial: first patient anticipated in early 2025
acute and chronic painsource ↗
◆First Patient DosedTrial
CG009301: first patient dosing anticipated in Q1 2025
blood cancers (AML, HR-MDS, ALL)source ↗
▲Trial InitiationPUR1900Trial
Cipla approved to proceed with Phase 3 trial of PUR1900 in India
allergic bronchopulmonary aspergillosissource ↗
▲Other Regulator MilestonePUR1900Ex-US Regulatory
India CDSCO approval to proceed with Phase 3 trial
allergic bronchopulmonary aspergillosissource ↗
▲Primary Endpoint MetPUR1900Clinical Data
Positive results from Phase 2 study of PUR1900 published
▼Program DiscontinuationPUR1900Corporate
Wind down of PUR1900 Phase 2b clinical trial completed
allergic bronchopulmonary aspergillosissource ↗
▲Trial InitiationTrial
CG001419 pain trial: HREC approval received, enrollment to begin
acute and chronic painsource ↗
▲IND ClearanceIND
CG009301: IND allowance received from China CDE
blood cancers (AML, HR-MDS, ALL)source ↗
▲Partnership / LicenseCorporate
Closed transactions with MannKind Corporation validating iSPERSE technology
▼Trial DiscontinuedPUR1900Trial
Completed PUR1900 wind down activities
allergic bronchopulmonary aspergillosissource ↗
●Trial CompletionPUR1900Trial
Complete Phase 2b wind down activities
allergic bronchopulmonary aspergillosissource ↗
▲Partnership / LicenseCorporate
MannKind to assume lease of Pulmatrix R&D facility and hire some R&D staff
◆Topline ReadoutPUR1900Clinical Data
Topline data anticipated
allergic bronchopulmonary aspergillosissource ↗
●Trial CompletionPUR1900Trial
Expected completion of all Phase 2b activities for PUR1900
fungal infectionssource ↗
▲Partnership / LicenseCorporate
Completed series of transactions with MannKind Corporation validating iSPERSE technology
▼Enrollment PausedPUR1900Trial
Stopped patient enrollment for PUR1900 Phase 2b study
allergic bronchopulmonary aspergillosissource ↗
▼Restructuring LayoffsCorporate
Continued cost saving measures and repositioning as virtual company
Past FDA Catalysts and PDUFA Decisions
How PULM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-03-31 | PUR3100 (orally inhaled dihydroergotamine, DHE) | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 88%
Micro Cap(rank 581 of 660)
Percentile Rank
Pulmatrix, Inc. faces pipeline headwinds (23/100), with $129M risk-adjusted pipeline value, led by PUR1800 in Chronic Obstructive Pulmonary Disease (COPD) (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PUR1800 Small moleculeCompletedNCT04759807 | Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | COMPLETED | 18 | Dec 2, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every PULM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PUR3100 | acute migraine | Phase 1 | 2024-05-15 | Cmax: 3620 · 14,400; AUC0 · 2h: 1120 · 4320; nausea incidence: 21% vs. 86%; vomiting incidence: 0% vs. 29%; headache incidence: 16% vs. 57%; mean time to Cmax: 5 vs. 5.5 min; minimum effective Cmax: 1000 pg/mLRead More | Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wasilewski MargaretOfficer (Chief Medical Officer) | Grant/Award | 21,060 21,060 held | $0.00 | 03/01/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in PULM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PULM for Q2 2026. | ||||
PULM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PULM ranks across every disease it competes in
Competitive Position is a premium feature
See how PULM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPULM News
PULM▼ -5.6%on this news
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Pulmatrix, Inc. announced its Q2 2026 financial results and progress on its merger with Eos SENOLYTIX. The merger is expected to close in Q3 2026, pending customary conditions. Pulmatrix highlighted advancements in its clinical assets, including PUR1900's Phase 3 approval in India and the IND acceptance for PUR3100's Phase 2 study. However, the company faces financial challenges with a notable decrease in cash reserves.
Read more →PULMPulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix, Inc. announced its first quarter 2026 financial results, highlighting a merger agreement with Eos SENOLYTIX and a successful private placement raising $1 million. The company is focusing on monetizing its clinical assets while preparing for a Phase 3 trial of PUR1900 in India. However, it reported a decrease in cash reserves and a net loss of $1.172 million.
Read more →PULMPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Pulmatrix, Inc. has successfully closed a private placement of Series B Convertible Preferred Stock, raising approximately $1 million. This investment, made by an affiliate of Eos SENOLYTIX, is part of Pulmatrix's planned merger with Eos. The funds will be utilized for working capital and general corporate purposes, marking a significant step in the merger process.
Read more →PULM▼ -28.8%on this news· ran to -39% by day 3
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix, Inc. and Eos SENOLYTIX, Inc. have announced a merger agreement to form a combined entity that will operate as Eos SENOLYTIX, targeting aging-related diseases using innovative mitochondrial therapies. The merger is expected to capitalize on $19 million in financing to advance their lead clinical candidate, PTC-2105, aimed at addressing sarcopenia and other age-related conditions. This merger highlights a strategic shift in obesity management, focusing not just on weight loss but on improving overall body composition and healthspan. The transaction has received unanimous approval from both companies' boards and is anticipated to close in mid-2026, pending customary regulatory approvals.
Read more →PULM▼ -36.8%on this news
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix has announced the termination of its merger agreement with Cullgen due to delays in regulatory approval from the China Securities Regulatory Commission. Following this, Pulmatrix is exploring alternative merger opportunities and has reported positive interest in potential transactions. The company remains focused on its development of inhaled therapeutic products.
Read more →PULM▼ -9.3%on this news· ran to -36% by day 3shared move
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Pulmatrix, Inc. reported its financial results for 2025, revealing a significant drop in revenues to nil. The company is focusing on completing its merger with Cullgen while exploring licensing options for its iSPERSE technology. Despite a decrease in cash reserves, Pulmatrix aims to fund operations into early 2027. The merger's completion is contingent on regulatory approvals.
Read more →PULM▼ -8.1%on this news· ran to -42% by day 3
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix and Cullgen have agreed to waive the "No Solicitation" clause in their merger agreement to explore alternative transactions while continuing to seek regulatory approval from the China Securities Regulatory Commission. Despite stockholder approval and preparation steps, the companies have not yet received necessary final approvals. Pulmatrix's fiscal health appears stable, expecting to fund operations through late 2026. The ongoing clinical development of their inhaled therapeutic products shows potential benefits for migraine and respiratory diseases.
Read more →PULMPulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Pulmatrix, Inc. announced its third quarter 2025 financial results and plans to divest its iSPERSE™ technology and related assets as part of a proposed merger with Cullgen. The merger aims to create a company focused on targeted protein degradation therapies. Financial results indicate a significant decrease in revenues and ongoing operational challenges.
Read more →PULMPulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
Pulmatrix, Inc. reported its second quarter 2025 financial results and outlined a divestment plan for its inhalation assets as it prepares for a merger with Cullgen. The merger aims to create a Nasdaq-listed entity focused on targeted protein degradation therapies. Financial results showed a significant decrease in revenues and ongoing operational challenges, including the winding down of clinical trials.
Read more →PULM▲ +6.6%on this news
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
Pulmatrix, Inc. announced its first quarter 2025 financial results and a divestment plan for its assets, including the Phase 2-ready acute migraine candidate, PUR3100. The company is in the process of merging with Cullgen, which is expected to close in June 2025. Financial results showed a decrease in revenues to $0, attributed to the completion of the PUR1900 trial. Pulmatrix's cash position is projected to sustain operations through the merger's anticipated closing.
Read more →PULMPulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Pulmatrix, Inc. reported its fourth-quarter and year-end financial results for 2024, highlighting a revenue increase due to a contract modification. The biopharmaceutical company is moving forward with a merger with Cullgen, anticipated to close in the first half of 2025, while planning to divest its clinical assets including the migraine treatment PUR3100. The company has seen a significant decrease in total assets and has incurred financial losses related to earlier transactions, which may affect its operational stability.
Read more →PULM▲ +73.7%on this news· ran to +228% by day 3
Pulmatrix and Cullgen Announce Proposed Merger
Pulmatrix and Cullgen have announced a planned merger that will result in a Nasdaq-listed entity focusing on targeted protein degradation technology. The combined company is expected to have approximately $65 million in cash to support upcoming clinical trials, including those for cancer and pain treatment. Following the merger, the ownership for pre-merger Pulmatrix shareholders will decrease significantly, as they will hold only 3.6% of the new entity. The merger is anticipated to close by the end of March 2025, pending shareholder and regulatory approvals.
Read more →PULMPulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its third quarter 2024 financial results, reporting a decrease in revenues primarily due to the wind down of the PUR1900 Phase 2b clinical trial. The company closed transactions with MannKind Corporation, which validates its iSPERSE™ technology. Despite a decrease in revenues, Pulmatrix projects a cash runway into Q4 2026, allowing for continued operational focus on strategic alternatives for its products.
Read more →PULMPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its second quarter 2024 financial results, highlighting a significant cash reserve that extends its operations into Q4 2026. The company has completed key transactions with MannKind Corporation, reaffirming the potential of its iSPERSE™ technology. Despite a decrease in revenues mainly due to the winding down of the PUR1900 Phase 2b study, Pulmatrix is exploring partnerships to advance its other drug candidates, particularly PUR3100 for acute migraines and PUR1800 for COPD. Positive Phase 1 results for PUR3100 were noted, alongside plans for a Phase 2 clinical study.
Read more →PULMPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix has entered a cross-license agreement with MannKind Corporation, allowing Pulmatrix to use MannKind's Cricket inhalation device for its PUR3100 formulation. MannKind will also assume the lease of Pulmatrix's Bedford R&D facility, enhancing collaboration on future drug development. This partnership aims to advance treatments for acute migraine and other neurological diseases.
Read more →PULMPulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix announced the publication of clinical results for its orally inhaled PUR3100, a formulation of dihydroergotamine for acute migraine treatment. The Phase 1 study demonstrated rapid pharmacokinetics and improved safety compared to intravenous DHE. The company is now preparing for a Phase 2 clinical trial to further explore PUR3100's efficacy.
Read more →PULMPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. reported its first quarter financial results for 2024, showing a revenue increase to $5.9 million and a net income of $0.8 million. The company has amended its partnership with Cipla, leading to the wind down of the PUR1900 Phase 2b study, which will reduce cash burn. Furthermore, Pulmatrix plans to focus on PUR3100, showing promising early trial results and is exploring additional partnerships to support its development pipeline.
Read more →PULM▲ +8%on this news
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. announced its financial results for Q4 and year-end 2023, highlighting a cash balance of $19.2 million projected to last until Q1 2026. The company has decided to wind down the PUR1900 Phase 2b study, transferring development responsibilities to Cipla while earning a small royalty on any future sales. Additionally, Pulmatrix received FDA acceptance for an IND application for PUR3100, prompting a Phase 2 study to investigate its safety and efficacy in migraine treatment. Positive results from past trials suggest progress for Pulmatrix's inhaled therapies amidst financial adjustments.
Read more →PULM▲ +8%on this news
Exhibti 99.1 Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cip
Pulmatrix, Inc. (PULM) announced its financial results for Q4 and the year 2023, reporting a cash position of $19.2 million which provides a runway into Q1 2026. The company is winding down the PUR1900 Phase 2b study to reduce cash burn and is shifting focus to PUR3100, for which the FDA has approved a Phase 2 study. Financially, Pulmatrix recorded a net loss of $14.1 million for the year, despite a revenue increase linked to its partnership with Cipla. The strategy involves minimizing cash expenditure while exploring strategic alternatives for its drug development programs.
Read more →About Pulmatrix, Inc.
Headquarters945 CONCORD STREET, FRAMINGHAM, MA, 01701
BIOPHARMAWATCH ELITE PLUS
Trade the next PULM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime